BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Optibrium Joins Hepatic and Cardiac Toxicity Systems Project and Expands R&D Team


10/8/2013 9:27:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, UK, 8 October, 2013 – Optibrium, a developer of software for drug discovery, today announced that it will join the HeCaToS (Hepatic and Cardiac Toxicity Systems) project, a major European project with the objective to efficiently investigate the health impact of compounds on the heart and liver. The EU is providing twelve million Euros for the project, which is co-ordinated by Maastricht UMC+.

In the course of the project, Optibrium will extend and advance its unique quantum mechanical models that predict metabolism by Cytochrome P450 enzymes, while further developments will focus on predicting the formation of reactive or toxic metabolites. The resulting models will be integrated into the HeCaToS system, to determine if metabolites of new compounds may damage the liver and heart, and support the project’s aim to enable the development of safer medications, cosmetics and industrial chemicals.

Optibrium has recruited new members to its R&D team to facilitate this project and simultaneously accelerate its software development plans. In particular, to lead its contribution to the HeCaToS project, Optibrium has appointed Dr Patrik Rydberg as Associate Director of Computational Chemistry. Patrik joins Optibrium from the Department of Drug Design and Pharmacology at the University of Copenhagen, where he was Associate Professor. As part of the P450 group in this department, Patrik led the development of the SMARTCyp software and undertook pioneering research on the prediction of metabolism. Patrik will also provide leadership on wider research efforts relating to Optibrium’s StarDrop software, adding his extensive computational chemistry experience to the development of this platform that guides the design and selection of high quality compounds in drug discovery.

Patrik commented, “I am delighted to be joining the Optibrium team and working on the HeCaToS project. This project, with its objective to better predict hepatic and cardiac toxicity, provides an exciting context in which to advance the field of metabolism prediction.”

For further information on Optibrium and StarDrop, please visit www.optibrium.com, contact info@optibrium.com or call +44 1223 815900. For more information on the HeCaToS project, please see the press release from Maastricht UMC+ at: http://www.mumc.nl/actueel/nieuws/veiliger-en-effectiever-chemicalien-testen-zonder-proefdieren.

Media contact

Sarah Jeffery

Zyme Communications

E-mail: sarah.jeffery@zymecommunications.com

Phone: +44 (0) 7771 730919

Optibrium

Nick Foster

Director, Business Development

E-mail: nick@optibrium.com

Phone: +44 (0)1223 815900

About Optibrium Ltd.

Optibrium provides drug discovery software solutions that bring confidence to the selection and design of high quality candidate drugs. The Company’s flagship platform, StarDrop, creates an intuitive, highly visual and flexible environment to facilitate and speed up lead identification and optimisation, quickly targeting effective drug candidates with a high probability of success downstream.

Founded in 2009, Optibrium continues to develop StarDrop and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators, that include leading global pharma companies, biotech and academic groups.

Visit the online community at http://www.optibrium.com/community/ for further discussions on improving the productivity of drug discovery.

About Maastricht UMC+

Maastricht University Medical Centre+ (Maastricht UMC+) is known both nationally and internationally for its focus on prevention, so not only rehabilitation but also health maintenance and health promotion. In addition to providing top-quality clinical and referral care, our core activities include scientific research and education/training. The hallmark the Maastricht UMC+ is its multidisciplinary and problem-based learning approach. The Maastricht university hospital, which has 715 beds, employs approximately 7,000 people, and educates 4,000 students, is a member of the NFU, the Netherlands Federation of University Medical Centres.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES